AbCellera and Biogen Inc. entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. Under the terms of the agreement, AbCellera will receive an upfront payment and is eligible to receive additional milestone payments should the research programs achieve certain research, developmental and regulatory milestones. AbCellera is also eligible to receive potential royalties on future net sales of products that result from the collaboration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 USD | -2.84% | -7.60% | -33.98% |
May. 07 | Transcript : AbCellera Biologics Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | AbCellera Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
234 USD | +1.83% | +6.98% | 34.09B | ||
3.77 USD | -2.84% | -7.60% | 1.11B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.98% | 1.11B | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.19% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- ABCL Stock
- News AbCellera Biologics Inc.
- AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions